Smith & Nephew SNATS (SNN) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed Smith & Nephew SNATS (SNN) over the past year, losing 14.8% versus a loss of 25.0%. Over five years, SNN leads with a -23.8% price change compared with -58.3% for TLSI. Smith & Nephew SNATS is the larger company by market cap ($11.36 billion vs $247.5 million), about 45.9 times the size.
Smith & Nephew SNATS pays a dividend yielding 1.46%, while TriSalus Life Sciences does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNN | TLSI |
|---|---|---|
| Share price | $27.14 | $4.02 |
| Market cap | $11.36B | $247.53M |
| 1-day change | +0.67% | -2.66% |
| YTD return | -17.83% | -40.83% |
| 1-year return | -24.97% | -14.85% |
| 5-year return | -23.82% | -58.28% |
| P/E ratio (TTM) | 18.46 | — |
| Forward P/E | 11.26 | — |
| EPS (TTM) | $1.47 | $-1.22 |
| Dividend yield | 1.46% | 0.00% |
| Annual dividend | $0.397 | $0.00 |
| Revenue (latest FY) | $6.16B | — |
| Revenue growth (YoY) | +6.09% | — |
| Net income (latest FY) | $625.00M | — |
| Gross margin | 68.01% | — |
| Operating margin | 12.88% | — |
| Net margin | 10.14% | — |
| 52-week high | $37.51 | $7.95 |
| 52-week low | $26.12 | $2.20 |
| Distance from 52-week high | -27.65% | -49.43% |
| Analyst consensus | hold | none |
| Avg. price target upside | +19.09% | +158.71% |
| Average volume | 1.65M | 275.38K |
| Shares outstanding | 418.52M | 61.57M |
| Employees | 17,000 | 102 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Smith & Nephew SNATS is about 45.9 times larger than TriSalus Life Sciences by market value ($11.36B vs $247.53M).
- TLSI has outperformed SNN by 10.1 percentage points over the past year.
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.46% vs 0.00%).
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Health Care · Industrial Specialties · 17,000 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
SNN vs TLSI FAQ
Which is bigger, Smith & Nephew SNATS or TriSalus Life Sciences?
Smith & Nephew SNATS (SNN) is larger, with a market capitalization of $11.36B compared with $247.53M for TriSalus Life Sciences (TLSI).
Which stock has performed better over the past year, SNN or TLSI?
TLSI returned -14.85% over the past 12 months, compared with -24.97% for SNN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Smith & Nephew SNATS or TriSalus Life Sciences?
Smith & Nephew SNATS pays a dividend yielding 1.46%, while TriSalus Life Sciences does not currently pay a regular dividend.
Are Smith & Nephew SNATS and TriSalus Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Smith & Nephew SNATS and Medical Specialities for TriSalus Life Sciences.